Insider · CIK 0001663607
Peter Evan Harwin
Files at ORKA (ARCA biopharma, Inc.), CBIO (GLYCOMIMETICS INC), COGT (Cogent Biosciences, Inc.), SYRE (Spyre Therapeutics, Inc.), KRSA (Cyclerion Therapeutics, Inc.), JBIO (Aerovate Therapeutics, Inc.), DMRA (Damora Therapeutics, Inc.), ZBIO (Zenas BioPharma, Inc.), APGE (Apogee Therapeutics, Inc.). First filing -, latest -.
In brief
Peter Evan Harwin files SEC Form 4 as director and 10% owner at ORKA (ARCA biopharma, Inc.), and also at CBIO (GLYCOMIMETICS INC), COGT (Cogent Biosciences, Inc.), SYRE (Spyre Therapeutics, Inc.), KRSA (Cyclerion Therapeutics, Inc.) and 4 more. No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Peter Evan Harwin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| Jun 4, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
Questions about Peter Evan Harwin
Answered from the filings on this page, as of the latest one.
Is Peter Evan Harwin buying or selling?
Peter Evan Harwin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Peter Evan Harwin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Evan Harwin has 0.
Where does Peter Evan Harwin file Form 4?
Peter Evan Harwin has filed Form 4 at ORKA (ARCA biopharma, Inc.); CBIO (GLYCOMIMETICS INC); COGT (Cogent Biosciences, Inc.); SYRE (Spyre Therapeutics, Inc.); KRSA (Cyclerion Therapeutics, Inc.) and 4 more. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.